These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36689092)

  • 1. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
    Magbanua MJM; van 't Veer L; Clark AS; Chien AJ; Boughey JC; Han HS; Wallace A; Beckwith H; Liu MC; Yau C; Wileyto EP; Ordonez A; Solanki TI; Hsiao F; Lee JC; Basu A; Brown Swigart L; Perlmutter J; Delson AL; Bayne L; Deluca S; Yee SS; Carpenter EL; Esserman LJ; Park JW; Chodosh LA; DeMichele A
    Breast Cancer Res Treat; 2023 Apr; 198(2):383-390. PubMed ID: 36689092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
    Wimberger P; Blohmer JU; Krabisch P; Link T; Just M; Sinn BV; Simon E; Solbach C; Fehm T; Denkert C; Kühn C; Rhiem K; Tesch H; Kümmel S; Petzold A; Stötzer O; Meisel C; Kuhlmann JD; Nekljudova V; Loibl S
    Breast Cancer Res; 2023 Mar; 25(1):32. PubMed ID: 36978142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
    Magbanua MJM; Yau C; Wolf DM; Lee JS; Chattopadhyay A; Scott JH; Bowlby-Yoder E; Hwang ES; Alvarado M; Ewing CA; Delson AL; Van't Veer LJ; Esserman L; Park JW
    Clin Cancer Res; 2019 Sep; 25(17):5388-5397. PubMed ID: 31142502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.
    Hartkopf AD; Taran FA; Wallwiener M; Hagenbeck C; Melcher C; Krawczyk N; Hahn M; Wallwiener D; Fehm T
    Breast Cancer Res; 2013; 15(5):R94. PubMed ID: 24099325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
    Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
    Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
    Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B
    Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.
    Cackowski FC; Wang Y; Decker JT; Sifuentes C; Weindorf S; Jung Y; Wang Y; Decker AM; Yumoto K; Szerlip N; Buttitta L; Pienta KJ; Morgan TM; Taichman RS
    Prostate; 2019 Oct; 79(14):1715-1727. PubMed ID: 31449673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy.
    Xu X; Zhao W; Liu C; Gao Y; Chen D; Wu M; Li C; Wang X; Song X; Yu J; Liu Z; Yu Z
    BMC Cancer; 2024 Jan; 24(1):13. PubMed ID: 38166846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.
    Hartkopf AD; Brucker SY; Taran FA; Harbeck N; von Au A; Naume B; Pierga JY; Hoffmann O; Beckmann MW; Rydén L; Fehm T; Aft R; Solà M; Walter V; Rack B; Schuetz F; Borgen E; Ta MH; Bittner AK; Fasching PA; Fernö M; Krawczyk N; Weilbaecher K; Margelí M; Hahn M; Jueckstock J; Domschke C; Bidard FC; Kasimir-Bauer S; Schoenfisch B; Kurt AG; Wallwiener M; Gebauer G; Klein CA; Wallwiener D; Janni W; Pantel K
    Eur J Cancer; 2021 Sep; 154():128-137. PubMed ID: 34265505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF; Yau C; Chen YY; Balassanian R; Klein ME; Pusztai L; Nanda R; Parker BA; Datnow B; Krings G; Wei S; Feldman MD; Duan X; Chen B; Sattar H; Khazai L; Zeck JC; Sams S; Mhawech-Fauceglia P; Rendi M; Sahoo S; Ocal IT; Fan F; LeBeau LG; Vinh T; Troxell ML; Chien AJ; Wallace AM; Forero-Torres A; Ellis E; Albain KS; Murthy RK; Boughey JC; Liu MC; Haley BB; Elias AD; Clark AS; Kemmer K; Isaacs C; Lang JE; Han HS; Edmiston K; Viscusi RK; Northfelt DW; Khan QJ; Leyland-Jones B; Venters SJ; Shad S; Matthews JB; Asare SM; Buxton M; Asare AL; Rugo HS; Schwab RB; Helsten T; Hylton NM; van 't Veer L; Perlmutter J; DeMichele AM; Yee D; Berry DA; Esserman LJ
    JAMA Oncol; 2021 Nov; 7(11):1654-1663. PubMed ID: 34529000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy.
    Solá M; Margelí M; Castellá E; Cirauqui B; Mariscal A; Rull M; Julian JF; Luna M; Vallejo V; Fraile M
    Breast; 2013 Oct; 22(5):908-13. PubMed ID: 23683695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score.
    Hartkopf AD; Wallwiener M; Kommoss S; Taran FA; Brucker SY
    Breast Cancer Res Treat; 2016 Feb; 156(1):91-5. PubMed ID: 26911294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
    Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
    Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
    Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
    JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.
    Falck AK; Bendahl PO; Ingvar C; Isola J; Jönsson PE; Lindblom P; Lövgren K; Rennstam K; Fernö M; Rydén L
    BMC Cancer; 2012 Sep; 12():403. PubMed ID: 22963449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
    Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
    Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.
    Synnestvedt M; Borgen E; Wist E; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Schirmer C; Nesland JM; Naume B
    BMC Cancer; 2012 Dec; 12():616. PubMed ID: 23259667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
    Yau C; Osdoit M; van der Noordaa M; Shad S; Wei J; de Croze D; Hamy AS; Laé M; Reyal F; Sonke GS; Steenbruggen TG; van Seijen M; Wesseling J; Martín M; Del Monte-Millán M; López-Tarruella S; ; Boughey JC; Goetz MP; Hoskin T; Gould R; Valero V; Edge SB; Abraham JE; Bartlett JMS; Caldas C; Dunn J; Earl H; Hayward L; Hiller L; Provenzano E; Sammut SJ; Thomas JS; Cameron D; Graham A; Hall P; Mackintosh L; Fan F; Godwin AK; Schwensen K; Sharma P; DeMichele AM; Cole K; Pusztai L; Kim MO; van 't Veer LJ; Esserman LJ; Symmans WF
    Lancet Oncol; 2022 Jan; 23(1):149-160. PubMed ID: 34902335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
    Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M
    Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.